GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » 10-Year ROIIC %

KalVista Pharmaceuticals (KalVista Pharmaceuticals) 10-Year ROIIC % : -514.89% (As of Apr. 2023)


View and export this data going back to 2015. Start your Free Trial

What is KalVista Pharmaceuticals 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. KalVista Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Apr. 2023 was -514.89%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for KalVista Pharmaceuticals's 10-Year ROIIC % or its related term are showing as below:

KALV's 10-Year ROIIC % is ranked worse than
86.65% of 1356 companies
in the Biotechnology industry
Industry Median: -35.045 vs KALV: -514.89

KalVista Pharmaceuticals 10-Year ROIIC % Historical Data

The historical data trend for KalVista Pharmaceuticals's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals 10-Year ROIIC % Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -514.89

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -514.89 - - -

Competitive Comparison of KalVista Pharmaceuticals's 10-Year ROIIC %

For the Biotechnology subindustry, KalVista Pharmaceuticals's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's 10-Year ROIIC % falls into.



KalVista Pharmaceuticals 10-Year ROIIC % Calculation

KalVista Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Apr. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -110.871 (Apr. 2023) - -1.833 (Dec. 2012) )/( 24.089 (Apr. 2023) - 2.912 (Dec. 2012) )
=-109.038/21.177
=-514.89%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


KalVista Pharmaceuticals  (NAS:KALV) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


KalVista Pharmaceuticals 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals (KalVista Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
Executives
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Edward P. Feener officer: Chief Scientific Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett director, officer: President and CEO BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Paul K. Audhya officer: Chief Medical Officer C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Benjamin L Palleiko officer: CFO and Secretary C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Christopher Yea officer: Chief Development Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Albert Cha director 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor director C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith officer: Senior VP, Development C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel officer: Senior Vice President Medical 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira director C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland director 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108